Role of cytokines and chemokines in cartilage and bone destruction in arthritis

Current Opinion in Orthopaedics

Volumn 13, Issue 5, 2002, Pages 351-362

  Goldring, Mary B ^a   Goldring, Steven R ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; CYTOKINE RECEPTOR; GENE PRODUCT;

ARTHROPATHY; ARTICULAR CARTILAGE; BONE ATROPHY; BONE DESTRUCTION; CARTILAGE DEGENERATION; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CYTOKINE PRODUCTION; EMBRYO DEVELOPMENT; GENE STRUCTURE; HUMAN; IMMUNOREGULATION; MOLECULAR CLONING; ORGANOGENESIS; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TISSUE REPAIR;

EID: 0036788225     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001433-200210000-00005     Document Type: Review

References (130)

1. Raisz LG: Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 1988, 318:818-828.
2. Parfitt AM: Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994, 55:273-286.
3. Ducy P, Schinke T, Karsenty G: The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000, 289:1501-1503.
4. Teitelbaum S: Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
5. Goldring SR, Gravallese EM: Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000, 12:195-199.
6. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone and Miner Res 2000, 15:2-12.
7. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
8. Felix R, Cecchini MG, Fleisch H: Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 1990, 127:2592-2594.
9. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, Tomoyasu A, Yano K, Goto M, Murakami A, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
10. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
11. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
12. Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillespie MT: Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999, 265:144-150.
13. Weitzmann MN, Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R: T cell activation induces human osteoclast formation via receptor activator of nuclear factor κB ligand-dependent and -independent mechanisms. J Bone Miner Res 2001, 16:328-337.
14. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, et al.: Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012.
15. Choi Y, Woo KM, Ko SH, Lee YJ, Park SJ, Kim HM, Kwon BS: Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 2001, 31:2179-2188.
16. Ogata Y, Kukita A, Kukita T, Komine M, Miyahara A, Miyazaki S, Kohashi O: A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J Immunol 1999, 162:2754-2760.
17. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY: Interleukin-15 mediates T cell-dependent regulation of tumour necrosis factor-α production in rheumatoid arthritis. Nature Med 1997, 3:189-195.
18. McInnes I, Liew F: Interleukin 15: a proinflammatory role in rheumatoid synovitis. Immunol Today 1998, 19:75-79.
19. Chen S, Guttridge D, Tang E, Shi S, Guan K, Wang C: Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor κB-independent bone morphogenetic protein/Smad signaling. J Biol Chem 2001, 276:39259-39263.
20. Tsuboi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y, Fujiyama K, Kiriyama T, Aoyagi T, Maeda K, et al.: Tumor necrosis factor-α and interleukin-1β increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999, 134:190-191.
21. Votta B, White J, Dodds R, James I, Connor J, Le-Rykaczewski E, Eichman C, Kumar S, Lark M, Gowen M: CKβ-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues. J Cell Physiol 2000, 183:196-207.
22. Fuller K, Owens J, Chambers T: Macrophage inflammatory protein-1 α and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. J Immunol 1995, 154:6065-6072.
23. Rothe L, Collin-Osdoby P, Chen Y, Sunyer T, Chaudhary L, Tsay A, Goldring S, Avioli L, Osdoby P: Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology 1998, 139:4353-4363.
24. Lisignoli G, Toneguzzi S, Pozzi C, Piacentini A, Riccio M, Ferruzzi A, Gualtieri G, Facchini A: Proinflammatory cytokines and chemokine production and expression by human osteoblasts isolated from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1999, 26:791-799.
25. Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H, Kurimoto M, Dunn AR, Martin TJ, Gillespie MT: Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 1998, 101:595-603.
26. Horwood N, Elliott J, Martin T, MT G: IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001, 166:4915-4921.
27. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, et al.: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000, 408:600-605.
28. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT: Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J Exp Med 1997, 185:1005-1012.
29. Makiishi-Shimobayashi C, Tsujimura T, Iwasaki T, Yamada N, Sugihara A, Okamura H, Hayashi S, Terada N: Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem Biophys Res Commun 2001, 281:361-366.
30. Wei S, Wang M-H, Teitelbaum S, Ross F: Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κβ and mitogen-activated protein kinase signaling. J Biol Chem 2002, 277:6622-6630.
31. Romas E, Gillespie M, Martin T: Involvement of receptor activator of NF-κβ ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
32. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, et al.: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 2002, 416:744-749.
33. Karsenty G: The genetic transformation of bone biology. Genes Dev 1999, 13:3037-3051.
34. Soriano P, Montgomery C, Geske R, Bradley A: Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64:693-702.
35. Lomaga M, Yeh W, Sarosi I, Duncan G, Furlonger C, Ho A, Morony S, Capparelli C G V, Kaufman S, et al.: TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999, 13:1015-1024.
36. McHugh K, Hodivala-Dilke K, Zheng M, Namba N, Lam J, Novack D, Feng X, Ross F, Hynes R, Teitelbaum S: Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000, 105:433-440.
37. Feldmann M, Maini RN: The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology 1999, 38:3-7.
38. Romas E, Martin TJ: Cytokines in the pathogenesis of osteoporosis. Osteoporos Int 1997, 7:S47-S53.
39. Funk JL, Cordaro LA, Wei H, Benjamin JB, Yocum DE: Synovium as a source of increased amino-terminal parathyroid hormone-related protein expression in rheumatoid arthritis; a possible role for locally produced parathyroid hormone-related protein in the pathogenesis of rheumatoid arthritis. J Clin Invest 1998, 101:1362-1371.
40. Okano K, Tsukazaki T, Ohtsuru A, Namba H, Osaki M, Iwasaki K, Yamashita S: Parathyroid hormone-related peptide in synovial fluid and disease activity of rheumatoid arthritis. Br J Rheumatol 1996, 35:1056-1062.
41. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P: IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001, 3:168-177.
42. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA: The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996, 137:4058-4060.
43. Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T, Koshihara Y: A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997, 240:279-286.
44. Suzuki Y, Tsutsumi Y, Nakagawa M, Suzuki H, Matsushita K, Beppu M, Aoki H, Ichikawa Y, Mizushima Y: Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatology (Oxford) 2001, 40:673-682.
45. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
46. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250-258.
47. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S: Involvement of receptor activator of nuclear factor κ-B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-269.
48. Pettit A, Hong J, von Stechow D, Muller R, Goldring S, Choi Y, Benoist C, Gravellese E: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699.
49. Redlich K, Hayer S, Maier A, Dunstan C, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S, et al.: Tumor necrosis factor-a-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002, 46:785-792.
50. Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M: The osteoprotegerin/receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand system in cartilage. Arthritis Rheum 2001, 44:2768-2776.
51. Hosaka S, Akahoshi T, Wada C, Kondo H: Expression of the chemokine superfamily in rheumatoid arthritis. Clin Exp Immunol 1994, 97:451-457.
52. Konig A, Krenn V, Toksoy A, Gerhard N, Gillitzer R: Mig, GRO α and RANTES messenger RNA expression in lining layer, infiltrates and different leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Virchows Arch 2000, 436:449-458.
53. Mack M, Bruhl H, Gruber R, Jaeger C, Cihak J, Eiter V, Plachy J, Stangassinger M, Uhlig K, Schattenkirchner M, et al.: Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. Arthritis Rheum 1999, 42:981-988.
54. Wedderburn L, Robinson N, Patel A, Varsani H, Woo P: Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2000, 43:765-774.
55. Goldring MB: The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 2000, 43:1916-1926.
56. Sandell LJ, Aigner T: Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 2001, 3:107-113.
57. Goldring MB: Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 2001, 1:817-829.
58. Fukui N, Purple DR, Sandell LJ: Cell biology of osteoarthritis: the chondrocyte's response to injury. Curr Rheum Rep 2001, 3:496-505.
59. Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B: Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 2001, 44:2263-2274.
60. Dahlberg L, Billinghurst RC, Manner P, Nelson F, Webb G, Ionescu M, Reiner A, Tanzer M, Zukor D, Chen H, et al.: Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum 2000, 43:673-682.
61. Yasuda T, Poole AR: A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway. Arthritis Rheum 2002, 46:138-148.
62. Evans CH, Ghivizzani SC, Herndon JH, Wasko MC, Reinecke J, Wehling P, Robbins PD: Clinical trials in the gene therapy of arthritis. Clin Orthop 2000:S300-307.
63. Bresnihan B: The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2001, 30 (Suppl 2):17-20.
64. Feldmann M, Maini RN: Anti-TNF α therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001, 19:163-196.
65. Mengshol JA, Mix KS, Brinckerhoff CE: Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum 2002, 46:13-20.
66. Amin AR, Dave M, Attur M, Abramson SB: COX-2, NO, and cartilage damage and repair. Curr Rheumatol Rep 2000, 2:447-453.
67. Bordji K, Grillasca JP, Gouze JN, Magdalou J, Schohn H, Keller JM, Bianchi A, Dauca M, Netter P, Terlain B: Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) α and γ and retinoid Z receptor in cartilage. PPARγ activation modulates the effects of interleukin-1β on rat chondrocytes. J Biol Chem 2000, 275:12243-12250.
68. Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J: Peroxisome proliferator-activated receptor γ activators inhibit interleukin-1β-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 2001, 44:595-607.
69. Fahmi H, Pelletier JP, Di Battista JA, Cheung HS, Fernandes JC, Martel-Pelletier J: Peroxisome proliferator-activated receptor γ activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. Osteoarthritis Cartilage 2002, 10:100-108.
70. Kalajdzic T, Faour WH, He QW, Fahmi H, Martel-Pelletier J, Pelletier JP, Di Battista JA: Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. Arthritis Rheum 2002, 46:494-506.
71. van den Berg WB: Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001, 3:18-26.
72. Horai R, Saijo S, Tanioka J, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000, 191:313-320.
73. Campbell IK, O'Donnell K, Lawlor KD, Wicks IP: Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 2001, 107:1519-1527.
74. Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, Yonezawa T, Saeki Y, Panayi GS, Pitzalis C, et al.: The role of TNF-α in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 2002, 41:329-337.
75. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB: IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999, 163:5049-5055.
76. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, Edwards CK, 3rd: Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000, 43:2648-2659.
77. Kyburz D, Carson DA, Corr M: The role of CD40 ligand and tumor necrosis factor α signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis Rheum 2000, 43:2571-2577.
78. Guedez YB, Whittington KB, Clayton JL, Joosten LA, van de Loo FA, van den Berg WB, Rosloniec EF: Genetic ablation of interferon-γ up-regulates interleukin-1β expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 2001, 44:2413-2424.
79. de Hooge AS, van De Loo FA, Arntz OJ, van Den Berg WB: Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol 2000, 157:2081-2091.
80. Bardos T, Kamath RV, Mikecz K, Glant TT: Anti-inflammatory and chondro-protective effect of TSG-6 (tumor necrosis factor-α-stimulated gene-6) in murine models of experimental arthritis. Am J Pathol 2001, 159:1711-1721.
81. Mindrescu C, Thorbecke GJ, Klein MJ, Vilcek J, Wisniewski HG: Amelioration of collagen-induced arthritis in DBA/1J mice by recombinant TSG-6, a tumor necrosis factor/interleukin-1-inducible protein. Arthritis Rheum 2000, 43:2668-2677.
82. Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, Clark IM, Cawston TE: The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002, 46:961-967.
83. Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD: Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 2000, 157:1187-1196.
84. Plater-Zyberk C, Buckton J, Thompson S, Spaull J, Zanders E, Papworth J, Life PF: Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum 2001, 44:2697-2702.
85. Li WQ, Dehnade F, Zafarullah M: Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 2001, 166:3491-3498.
86. Van Den Berg WB: Lessons from animal models of arthritis. Curr Rheumatol Rep 2002, 4:232-239.
87. Lubberts E, Joosten LA, van de Loo FA, van den Gersselaar LA, van den Berg WB: Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum 2000, 43:1300-1306.
88. Dudler J, Renggli-Zulliger N, Busso N, Lotz M, So A: Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann Rheum Dis 2000, 59:529-532.
89. Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, Filvaroff EH: Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 2001, 16:10-21.
90. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA, van den Berg WB: IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
91. Chabaud M, Page G, Miossec P: Enhancing effect of IL-1, IL-17, and TNF-α on macrophage inflammatory protein-3α production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001, 167:6015-6020.
92. Bush FA, Farmer KM, Walker JS, Kirkham BW: Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002, 46:802-805.
93. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001, 12:53-72.
94. Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, Campbell C, Cunha F, Liew FY, McInnes IB: A role for IL-18 in neutrophil activation. J Immunol 2001, 167:2879-2886.
95. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE: Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001, 167:1644-1653.
96. Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY: Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001, 166:517-521.
97. Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van De Loo FA, Graber P, Aloni S, Cirillo R, et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001, 108:1825-1832.
98. Joosten LA, van De Loo FA, Lubberts E, Helsen MM, Netea MG, van Der Meer JW, Dinarello CA, van Den Berg WB: An IFN-γ-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol 2000, 165:6553-6558.
99. van den Berg WB: Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001, 30:7-16.
100. Arend WP, Gabay C: Physiologic role of interleukin-1 receptor antagonist. Arthritis Res 2000, 2:245-248.
101. Woods JM, Katschke KJ, Jr., Tokuhira M, Kurata H, Arai KI, Campbell PL, Koch AE: Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium. J Immunol 2000, 165:2755-2763.
102. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, Feldmann M: Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996, 39:495-503.
103. Lubberts E, Joosten LAB, van de Loo FAJ, van Den Bersselaar LAM, van den Berg WB: Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum 2000, 43:1300-1306.
104. Lubberts E, Joosten LA, Van Den Bersselaar L, Helsen MM, Bakker AC, Xing Z, Richards CD, Van Den Berg WB: Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Clin Exp Immunol 2000, 120:375-383.
105. van Roon JAG, Lafeber FPJG, Bijlsma JWJ: Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001, 44:3-12.
106. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD: Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001, 166:3499-3505.
107. Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, Mule JJ, McDonagh KT, Fox DA: Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001, 107:1275-1284.
108. Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, van Den Berg WB: IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000, 105:1697-1710.
109. Johansson AC, Hansson AS, Nandakumar KS, Backlund J, Holmdahl R: IL-10-deficient B 10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol 2001, 167:3505-3512.
110. Ortmann RA, Shevach EM: Susceptibility to collagen-induced arthritis: cytokine-mediated regulation. Clin Immunol 2001, 98:109-118.
111. Morel JO, Park CC, Kumar P, Koch AE: Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFκB activation. Lab Invest 2001, 81:1371-1383.
112. Borzi RM, Mazzetti I, Cattini L, Uguccioni M, Baggiolini M, Facchini A: Human chondrocytes express functional chemokine receptors and release matrix-degrading enzymes in response to C-X-C and C-C chemokines. Arthritis Rheum 2000, 43:1734-1741.
113. Yuan GH, Masuko-Hongo K, Sakata M, Tsuruha J, Onuma H, Nakamura H, Aoki H, Kato T, Nishioka K: The role of C-C chemokines and their receptors in osteoarthritis. Arthritis Rheum 2001, 44:1056-1070.
114. Alaaeddine N, Olee T, Hashimoto S, Creighton-Achermann L, Lotz M: Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum 2001, 44:1633-1643.
115. Kanbe K, Takagishi K, Chen Q: Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. Arthritis Rheum 2002, 46:130-137.
116. Schwarz EM, Looney RJ, O'Keefe RJ: Anti-TNF-α therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res 2000, 2:165-168.
117. Reddi AH: Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: noggin, chordin and DAN. Arthritis Res 2001, 3:1-5.
118. Edwards CJ, Francis-West PH: Bone morphogenetic proteins in the development and healing of synovial joints. Semin Arthritis Rheum 2001, 31:33-42.
119. Majumdar MK, Wang E, Morris EA: BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1. J Cell Physiol 2001, 189:275-284.
120. Bakker AC, van de Loo FA, van Beuningen HM, Sime P, van Lent PL, van der Kraan PM, Richards CD, van den Berg WB: Overexpression of active TGF-β-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. Osteoarthritis Cartilage 2001, 9:128-136.
121. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB: Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor-β injections. Osteoarthritis Cartilage 2000, 8:25-33.
122. Yamanishi Y, Boyle DL, Clark M, Maki RA, Tortorella MD, Arner EC, Firestein GS: Expression and regulation of aggrecanase in arthritis: the role of TGF-β. J Immunol 2002, 168:1405-1412.
123. Whellams EJ, Maile LA, Fernihough JK, Billingham ME, Holly JM: Alterations in insulin-like growth factor binding protein-3 proteolysis and complex formation in the arthritic joint. J Endocrinol 2000, 165:545-556.
124. Neidel J: Changes in systemic levels of insulin-like growth factors and their binding proteins in patients with rheumatoid arthritis. Clin Exp Rheumatol 2001, 19:81-84.
125. Matsumoto T, Tsurumoto T: Inappropriate serum levels of IGF-I and IGFBP-3 in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002, 41:352-353.
126. Loeser RF, Shanker G: Autocrine stimulation by insulin-like growth factor 1 and insulin-like growth factor 2 mediates chondrocyte survival in vitro. Arthritis Rheum 2000, 43:1552-1559.
127. Loeser RF, Shanker G, Carlson CS, Gardin JF, Shelton BJ, Sonntag WE: Reduction in the chondrocyte response to insulin-like growth factor 1 in aging and osteoarthritis: studies in a non-human primate model of naturally occurring disease. Arthritis Rheum 2000, 43:2110-2120.
128. Smith P, Shuler FD, Georgescu HI, Ghivizzani SC, Johnstone B, Niyibizi C, Robbins PD, Evans CH: Genetic enhancement of matrix synthesis by articular chondrocytes: comparison of different growth factor genes in the presence and absence of interleukin-1. Arthritis Rheum 2000, 43:1156-1164.
129. Kaps C, Bramlage C, Smolian H, Haisch A, Ungethum U, Burmester GR, Sittinger M, Gross G, Haupl T: Bone morphogenetic proteins promote cartilage differentiation and protect engineered artificial cartilage from fibroblast invasion and destruction. Arthritis Rheum 2002, 46:149-162.
130. Borzi RM, Mazzetti I, Macor S, Silvestri T, Bassi A, Cattini L, Facchini A: Flow cytometric analysis of intracellular chemokines in chondrocytes in vivo: constitutive expression and enhancement in osteoarthritis and rheumatoid arthritis. FEBS Lett 1999, 455:238-242.